Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr

Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve...

Full description

Saved in:
Bibliographic Details
Published inBioconjugate chemistry Vol. 36; no. 4; pp. 748 - 761
Main Authors Petrov, Stanislav A., Grigoriev, Gleb P., Orlov, Grigory A., Zyk, Nikolay Y., Grishin, Yuri K., Roznyatovsky, Vitaly A., Beloglazkina, Maria A., Petrova, Juliana V., Machulkin, Aleksei E., Larkina, Mariia S., Prach, Anastasia, Varvashenya, Ruslan, Bodenko, Vitalina, Plotnikov, Evgenii, Yusubov, Mekhman S., Beloglazkina, Elena K.
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 16.04.2025
Subjects
Online AccessGet full text
ISSN1043-1802
1520-4812
1520-4812
DOI10.1021/acs.bioconjchem.5c00033

Cover

Loading…
Abstract Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26 x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the K D and B max using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.
AbstractList Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26 x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the K D and B max using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.
Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.
Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.
Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand and its HBV conjugate with DOTA , the complete signal assignment in H, C, and N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the and using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.
Author Larkina, Mariia S.
Roznyatovsky, Vitaly A.
Yusubov, Mekhman S.
Machulkin, Aleksei E.
Zyk, Nikolay Y.
Varvashenya, Ruslan
Petrova, Juliana V.
Grigoriev, Gleb P.
Petrov, Stanislav A.
Grishin, Yuri K.
Plotnikov, Evgenii
Prach, Anastasia
Beloglazkina, Elena K.
Orlov, Grigory A.
Beloglazkina, Maria A.
Bodenko, Vitalina
AuthorAffiliation Department of Chemistry
Department of Organic Chemistry
People’s Friendship University of Russia Named after Patrice Lumumba (RUDN University)
The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute
Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences
Scientific and Educational Laboratory of Chemical and Pharmaceutical Research
Tomsk National Research Medical Center, Russian Academy of Sciences
Department of Biochemistry
AuthorAffiliation_xml – name: Department of Organic Chemistry
– name: People’s Friendship University of Russia Named after Patrice Lumumba (RUDN University)
– name: Department of Chemistry
– name: Tomsk National Research Medical Center, Russian Academy of Sciences
– name: The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute
– name: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research
– name: Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences
– name: Department of Biochemistry
Author_xml – sequence: 1
  givenname: Stanislav A.
  orcidid: 0000-0002-6000-6100
  surname: Petrov
  fullname: Petrov, Stanislav A.
  email: stanislavpetrovsh1994@gmail.com
  organization: Department of Chemistry
– sequence: 2
  givenname: Gleb P.
  surname: Grigoriev
  fullname: Grigoriev, Gleb P.
  organization: Department of Chemistry
– sequence: 3
  givenname: Grigory A.
  surname: Orlov
  fullname: Orlov, Grigory A.
  organization: Department of Chemistry
– sequence: 4
  givenname: Nikolay Y.
  surname: Zyk
  fullname: Zyk, Nikolay Y.
  organization: Department of Chemistry
– sequence: 5
  givenname: Yuri K.
  surname: Grishin
  fullname: Grishin, Yuri K.
  organization: Department of Chemistry
– sequence: 6
  givenname: Vitaly A.
  surname: Roznyatovsky
  fullname: Roznyatovsky, Vitaly A.
  organization: Department of Chemistry
– sequence: 7
  givenname: Maria A.
  surname: Beloglazkina
  fullname: Beloglazkina, Maria A.
  organization: Department of Chemistry
– sequence: 8
  givenname: Juliana V.
  orcidid: 0000-0003-4680-5755
  surname: Petrova
  fullname: Petrova, Juliana V.
  organization: People’s Friendship University of Russia Named after Patrice Lumumba (RUDN University)
– sequence: 9
  givenname: Aleksei E.
  orcidid: 0000-0001-7975-0346
  surname: Machulkin
  fullname: Machulkin, Aleksei E.
  organization: People’s Friendship University of Russia Named After Patrice Lumumba (RUDN University)
– sequence: 10
  givenname: Mariia S.
  orcidid: 0000-0003-1176-2441
  surname: Larkina
  fullname: Larkina, Mariia S.
  organization: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research
– sequence: 11
  givenname: Anastasia
  surname: Prach
  fullname: Prach, Anastasia
  organization: Tomsk National Research Medical Center, Russian Academy of Sciences
– sequence: 12
  givenname: Ruslan
  surname: Varvashenya
  fullname: Varvashenya, Ruslan
  organization: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research
– sequence: 13
  givenname: Vitalina
  surname: Bodenko
  fullname: Bodenko, Vitalina
  organization: Scientific and Educational Laboratory of Chemical and Pharmaceutical Research
– sequence: 14
  givenname: Evgenii
  surname: Plotnikov
  fullname: Plotnikov, Evgenii
  organization: Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences
– sequence: 15
  givenname: Mekhman S.
  surname: Yusubov
  fullname: Yusubov, Mekhman S.
  organization: Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences
– sequence: 16
  givenname: Elena K.
  orcidid: 0000-0001-6796-8241
  surname: Beloglazkina
  fullname: Beloglazkina, Elena K.
  organization: Department of Chemistry
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40176353$$D View this record in MEDLINE/PubMed
BookMark eNqFkU1vEzEQhi1URD_gL4AlLlw22B5v1nuMArRIrVKRcLa83tlko40dbC8i_76OklaIC5eZkeZ5Z0bzXpML5x0S8oGzCWeCfzY2TpreW--2doO7SWkZYwCvyBUvBSuk4uIi10xCwRUTl-Q6xm1Gaq7EG3IpGa-mUMIV-TPf-N4i9R01ji72qd-ZgT74dhxMoMsUTML1gXY-0LRBujy4nGIfj4Ivi9WsmHuXTO96t6Z3mDD4pv9tBnSJztY5RroyYY3p2H9cPszylpbe_ngMb8nrzgwR353zDfn57etqflfcL26_z2f3hQGAVABUjZW15LLtFAcL0NWiwrpWDZNobQd1qawxosSKoWxLqGopUcqpYNOmaeGGfDrN3Qf_a8SY9K6PFofBOPRj1MBVWSlVS5bRj_-gWz8Gl6_TIBgvy4orlan3Z2psdtjqfcgvCwf9_NMMVCfABh9jwO4F4Uwf3dPZPf2Xe_rsXlbCSXkEXnb_T_UEELihlA
Cites_doi 10.1002/pros.22789
10.1021/acsomega.4c00489
10.1021/jm020515w
10.1021/acsmedchemlett.4c00324
10.1016/S0090-4295(96)00184-7
10.1021/jm100729b
10.1097/MNM.0000000000001520
10.1002/psc.2836
10.1016/j.jscs.2010.12.006
10.1021/bc025536j
10.1016/1078-1439(95)00002-Y
10.3390/pharmaceutics11070358
10.1021/bc200279b
10.3390/cancers13225766
10.3390/molecules22040523
10.18632/oncotarget.9004
10.1021/acs.jmedchem.0c01785
10.2967/jnumed.109.064444
10.1016/j.nucmedbio.2014.01.001
10.1007/s00726-010-0546-y
10.1097/MNM.0000000000000966
10.3390/pharmaceutics12070614
10.1016/j.bmc.2004.06.031
10.1021/jm0001774
10.1039/c39940002559
10.1021/bc300659k
10.1021/acs.jmedchem.5b01268
10.1016/j.molstruc.2021.130127
10.1021/bc4005377
10.1021/jm401703a
10.1016/j.bmcl.2019.01.040
10.1021/jm300488m
10.1016/j.nucmedbio.2021.03.005
10.1021/acsmedchemlett.3c00057
10.1016/j.humpath.2006.11.012
10.1021/acs.bioconjchem.5b00687
10.2967/jnumed.114.147413
10.3390/pharmaceutics16111358
10.1016/j.bioorg.2019.103154
10.3322/caac.21492
10.1021/jm051019l
10.1021/acs.jmedchem.5b01210
10.3390/cancers11091371
10.1021/acs.bioconjchem.5b00679
10.1002/pros.22784
10.1021/acsptsci.4c00070
10.1046/j.1525-1411.2001.003001001.x
10.3390/ph16050674
10.1007/s10967-018-6285-3
10.1002/jlcr.3749
10.3390/cancers15020442
ContentType Journal Article
Copyright 2025 American Chemical Society
Copyright American Chemical Society 2025
Copyright_xml – notice: 2025 American Chemical Society
– notice: Copyright American Chemical Society 2025
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7TM
8FD
FR3
P64
7X8
DOI 10.1021/acs.bioconjchem.5c00033
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Biotechnology Research Abstracts
Nucleic Acids Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Nucleic Acids Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList
Engineering Research Database
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Biology
EISSN 1520-4812
EndPage 761
ExternalDocumentID 40176353
10_1021_acs_bioconjchem_5c00033
e96468030
Genre Journal Article
GroupedDBID ---
-~X
23N
4.4
55A
5GY
5VS
7~N
AABXI
ABJNI
ABMVS
ABQRX
ABUCX
ACGFS
ACIWK
ACJ
ACPRK
ACS
ADHLV
AEESW
AENEX
AFEFF
AFRAH
AGXLV
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
CUPRZ
DU5
EBS
ED~
F5P
GGK
GNL
IH9
JG~
LG6
P2P
PQQKQ
ROL
TN5
TWZ
UI2
VF5
VG9
W1F
XKZ
YZZ
AAYXX
ABBLG
ABLBI
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7TM
8FD
FR3
P64
7X8
ID FETCH-LOGICAL-a333t-337bc49414df813c33f927e998b04eccf3958caa25e70e4d537944e446206bbd3
IEDL.DBID ACS
ISSN 1043-1802
1520-4812
IngestDate Wed Jul 02 05:08:09 EDT 2025
Mon Jun 30 08:30:21 EDT 2025
Thu Apr 17 08:38:14 EDT 2025
Sun Jul 06 05:07:17 EDT 2025
Thu Apr 17 08:51:30 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
License https://doi.org/10.15223/policy-029
https://doi.org/10.15223/policy-037
https://doi.org/10.15223/policy-045
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a333t-337bc49414df813c33f927e998b04eccf3958caa25e70e4d537944e446206bbd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-1176-2441
0000-0001-7975-0346
0000-0001-6796-8241
0000-0002-6000-6100
0000-0003-4680-5755
PMID 40176353
PQID 3201557188
PQPubID 45565
PageCount 14
ParticipantIDs proquest_miscellaneous_3185788940
proquest_journals_3201557188
pubmed_primary_40176353
crossref_primary_10_1021_acs_bioconjchem_5c00033
acs_journals_10_1021_acs_bioconjchem_5c00033
PublicationCentury 2000
PublicationDate 2025-04-16
PublicationDateYYYYMMDD 2025-04-16
PublicationDate_xml – month: 04
  year: 2025
  text: 2025-04-16
  day: 16
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Washington
PublicationTitle Bioconjugate chemistry
PublicationTitleAlternate Bioconjugate Chem
PublicationYear 2025
Publisher American Chemical Society
Publisher_xml – name: American Chemical Society
References ref9/cit9
ref45/cit45
ref3/cit3
ref27/cit27
ref56/cit56
ref16/cit16
Schuhmacher J. (ref55/cit55) 2005; 46
ref52/cit52
ref23/cit23
ref31/cit31
ref2/cit2
Israeli R. S. (ref8/cit8) 1994; 54
ref34/cit34
ref37/cit37
ref20/cit20
ref48/cit48
ref17/cit17
ref10/cit10
ref35/cit35
ref53/cit53
ref19/cit19
ref21/cit21
ref42/cit42
ref46/cit46
ref49/cit49
ref13/cit13
ref24/cit24
ref38/cit38
Markwalder R. (ref4/cit4) 1999; 59
ref54/cit54
ref6/cit6
ref36/cit36
ref18/cit18
Benoiton N. L. (ref50/cit50) 2006
ref11/cit11
ref25/cit25
ref29/cit29
ref32/cit32
ref39/cit39
ref14/cit14
ref5/cit5
ref51/cit51
ref43/cit43
ref28/cit28
Bandari R. P. (ref40/cit40) 2018; 5
ref26/cit26
ref12/cit12
ref15/cit15
ref41/cit41
ref22/cit22
ref33/cit33
ref30/cit30
ref47/cit47
ref1/cit1
ref44/cit44
ref7/cit7
References_xml – ident: ref17/cit17
  doi: 10.1002/pros.22789
– ident: ref23/cit23
  doi: 10.1021/acsomega.4c00489
– ident: ref11/cit11
  doi: 10.1021/jm020515w
– ident: ref32/cit32
  doi: 10.1021/acsmedchemlett.4c00324
– ident: ref5/cit5
  doi: 10.1016/S0090-4295(96)00184-7
– ident: ref45/cit45
  doi: 10.1021/jm100729b
– ident: ref33/cit33
  doi: 10.1097/MNM.0000000000001520
– ident: ref48/cit48
  doi: 10.1002/psc.2836
– ident: ref49/cit49
  doi: 10.1016/j.jscs.2010.12.006
– ident: ref46/cit46
  doi: 10.1021/bc025536j
– ident: ref6/cit6
  doi: 10.1016/1078-1439(95)00002-Y
– ident: ref30/cit30
  doi: 10.3390/pharmaceutics11070358
– ident: ref16/cit16
  doi: 10.1021/bc200279b
– ident: ref22/cit22
  doi: 10.3390/cancers13225766
– ident: ref3/cit3
  doi: 10.3390/molecules22040523
– ident: ref56/cit56
  doi: 10.18632/oncotarget.9004
– ident: ref38/cit38
  doi: 10.1021/acs.jmedchem.0c01785
– ident: ref53/cit53
  doi: 10.2967/jnumed.109.064444
– ident: ref39/cit39
  doi: 10.1016/j.nucmedbio.2014.01.001
– ident: ref27/cit27
  doi: 10.1007/s00726-010-0546-y
– ident: ref36/cit36
  doi: 10.1097/MNM.0000000000000966
– ident: ref41/cit41
  doi: 10.3390/pharmaceutics12070614
– ident: ref10/cit10
  doi: 10.1016/j.bmc.2004.06.031
– volume: 46
  start-page: 691
  issue: 4
  year: 2005
  ident: ref55/cit55
  publication-title: J. Nucl. Med.
– volume: 54
  start-page: 1807
  issue: 7
  year: 1994
  ident: ref8/cit8
  publication-title: Cancer Res.
– ident: ref9/cit9
  doi: 10.1021/jm0001774
– ident: ref47/cit47
  doi: 10.1039/c39940002559
– ident: ref51/cit51
  doi: 10.1021/bc300659k
– ident: ref20/cit20
  doi: 10.1021/acs.jmedchem.5b01268
– ident: ref52/cit52
  doi: 10.1016/j.molstruc.2021.130127
– ident: ref25/cit25
  doi: 10.1021/bc4005377
– ident: ref14/cit14
  doi: 10.1021/jm401703a
– ident: ref44/cit44
  doi: 10.1016/j.bmcl.2019.01.040
– ident: ref13/cit13
  doi: 10.1021/jm300488m
– ident: ref28/cit28
  doi: 10.1016/j.nucmedbio.2021.03.005
– ident: ref34/cit34
  doi: 10.1021/acsmedchemlett.3c00057
– volume: 59
  start-page: 1152
  issue: 5
  year: 1999
  ident: ref4/cit4
  publication-title: Cancer Res.
– ident: ref7/cit7
  doi: 10.1016/j.humpath.2006.11.012
– ident: ref31/cit31
  doi: 10.1021/acs.bioconjchem.5b00687
– ident: ref19/cit19
  doi: 10.2967/jnumed.114.147413
– ident: ref37/cit37
  doi: 10.3390/pharmaceutics16111358
– ident: ref1/cit1
  doi: 10.1016/j.bioorg.2019.103154
– ident: ref2/cit2
  doi: 10.3322/caac.21492
– ident: ref12/cit12
  doi: 10.1021/jm051019l
– ident: ref18/cit18
  doi: 10.1021/acs.jmedchem.5b01210
– ident: ref29/cit29
  doi: 10.3390/cancers11091371
– ident: ref15/cit15
  doi: 10.1021/acs.bioconjchem.5b00679
– ident: ref26/cit26
  doi: 10.1002/pros.22784
– ident: ref43/cit43
  doi: 10.1021/acsptsci.4c00070
– volume-title: Chemistry of Peptide Synthesis
  year: 2006
  ident: ref50/cit50
– ident: ref54/cit54
  doi: 10.1046/j.1525-1411.2001.003001001.x
– ident: ref21/cit21
  doi: 10.3390/ph16050674
– volume: 5
  start-page: 11
  issue: 1
  year: 2018
  ident: ref40/cit40
  publication-title: Chem. Biol. Lett.
– ident: ref35/cit35
  doi: 10.1007/s10967-018-6285-3
– ident: ref24/cit24
  doi: 10.1002/jlcr.3749
– ident: ref42/cit42
  doi: 10.3390/cancers15020442
SSID ssj0009182
Score 2.4639747
Snippet Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule....
SourceID proquest
pubmed
crossref
acs
SourceType Aggregation Database
Index Database
Publisher
StartPage 748
SubjectTerms Antigens, Surface - metabolism
Cell Line, Tumor
Chelating agents
Chelating Agents - chemistry
Chelation
Conjugates
Diagnostic agents
Gastrin
Gastrin-releasing peptide
Glutamate Carboxypeptidase II - metabolism
Heterocyclic Compounds, 1-Ring - chemistry
Humans
Ligands
Male
NMR
Nuclear magnetic resonance
Pharmacology
Prostate
Prostate cancer
Prostatic Neoplasms
Radioactive tracers
Radiopharmaceuticals - chemical synthesis
Radiopharmaceuticals - chemistry
Receptors
Receptors, Bombesin - metabolism
Spectra
Stereoselectivity
Synthesis
Tumor cells
Title Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr
URI http://dx.doi.org/10.1021/acs.bioconjchem.5c00033
https://www.ncbi.nlm.nih.gov/pubmed/40176353
https://www.proquest.com/docview/3201557188
https://www.proquest.com/docview/3185788940
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NIcReGGx8FAYYCfFEuvgjifOYFUaFVDatnbS3yHZsUaYmaGklyl_POR_b0DQNnhLFsR3bZ9_vcuefAd5Tqa0LqQsQLNtApMoF0jEXJCFVNHKRccZ7dCff4vGp-HoWnW0AvcWDz-i-MvVQzyu0Dn9gMxbDyHgcz-_BfRYj2PZoaDS94tmlsnVweuZN6YN33t5RkFdLpv5bLd2CNRudc7gNJ_3OnTbU5Hy4Wuqh-X2TyPHfm_MYHnUIlGStyDyBDVvuwG5WovW9WJMPpIkJbX6278CDg_7u4ag_GW4Xfo2-V7i-kMoRVZIjXHQWWOCkKnxIK-n4btcE4TBBeEmm6xIv9bz2GT4dzbLAU2K1J1OQsQ_HqfQcBR7VH8n8Tq-azJr4dJ9-PJ1kWEtBvpwcXzyF08PPs9E46E5wCBTnfBlwnmgjUkFF4STlhnOXssSiiadDgcLjeBpJoxSLbBJaUUQclwdh0URlYax1wZ_BZlmV9gWQNFaJkjqROmYC86XWFDFLTaJF4oyJB_ARuzbvZmCdN851RnP_8Fp_511_DyDsxzv_2fJ63J1lr5eLq2o486ATFbwcwLvLZBwP73dRpa1W-I7n25IyFeEAnrfydFknmreeEpC__L_PfwVbzB9E7Ekn4z3YXF6s7GtER0v9ppkPfwAB9QvE
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED-NITRe-Nj4KAxmJMQTKYntJM5jKIwC6zbRTtqeotixRUFN0NJKlL-euyRtAQlN8JQojr8vvt_lzj8DPA-Uts4PnIdg2XoyyZ2nHHde7Ad5ELrQOEMe3dFxNDyTH87D8y1Qq70w2IgaS6obJ_6GXSB4Rc_0tEIj8Qv2ZtYPDcF5cQ2uIyThFMyXDsYbut1AtX5OIuBUFMNzcEVBpJ1M_bt2-gvkbFTP4W24WDe6iTj52l_Mdd_8-IPP8X96dQdudXiUpa0A3YUtW-7CXlqiLT5bshesiRBtfr3vwo3Xq7udweqcuD34Pvhc4WrDKsfykp3gEjTDAkdVQQGurGO_XTIExwzBJhsvS7zU05oyvDmZpB4RZLXnVLAhBedUeorij8qQpbTvq2aTJlqd0k_HoxRrKdi7T6eX9-Ds8O1kMPS68xy8XAgx94SItZGJDGThVCCMEC7hsUWDT_sSRcmJJFQmz3loY9_KIhS4WEiLBiv3I60LcR-2y6q0D4ElUR7nSsdKR1xivsSaIuKJibWMnTFRD17i0Gbd91hnjaudBxk9_GW8s268e-Cvpj371rJ8XJ1lfyUem2oEJwiK6l714Nk6GeeDvDB5aasFvkPsW0ol0u_Bg1as1nWisUsEgeLRvzX_AHaGk9FRdvT--ONjuMnpiGKio4z2YXt-ubBPEDfN9dPmE_kJNRkUJQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3rb9MwED-NIR5feGw8CoMZCfGJlCR2EkfiS-go5dGtop20L1MUO7YoqMm0tBLlr-cujw6Q0ASfEtnx--y7y51_B_Dck8pY17MOCsvGEXFmHWl960Sul3mBDbTVZNEdH4ajY_HhJDjZgtfdXRjsRIU1VbURn3b1WW5bhAHvFaWreYmK4lcc0aIfaBLp-RW4SsY7cuhLBtMLyF1PNrZOAuGU5Mezf0lFxKF09TuH-ovYWbOf4W043XS89jr51l8tVV__-APT8X9HdgdutXIpSxpCugtbptiB3aRAnXyxZi9Y7Sla_4LfgWtvurcbgy5e3C58H3wp8dRhpWVZwY7wKFpgheMyJ0dX1qLgrhkKyQyFTjZdF_io5hUVODiaJQ4BZTXxKtiInHRKNcdtgEyRJXT_q2Kz2mud8ifTcYKt5Ozd58n5PTgevp0NRk4b18HJOOdLh_NIaRELT-RWelxzbmM_Mqj4KVcgSVkeB1JnmR-YyDUiDzgeGsKg4uq7oVI5vw_bRVmYh8DiMIsyqSKpQl9gudjoPPRjHSkRWa3DHrzEqU3bfVmltcnd91JK_GW-03a-e-B2S5-eNWgflxfZ60jkohnukyiKbF_24NkmG9eDrDFZYcoVfkMoXFLGwu3Bg4a0Nm2i0ktAgfzRv3V_H65PDobpp_eHHx_DTZ8iFRMqZbgH28vzlXmC4tNSPa13yU8Suhao
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Choice+of+an+Optimal+Modular+Strategy+for+the+Synthesis+of+DOTA-Containing+Heterobivalent+Agents+Targeting+PSMA+and+GRPr&rft.jtitle=Bioconjugate+chemistry&rft.au=Petrov%2C+Stanislav+A.&rft.au=Grigoriev%2C+Gleb+P.&rft.au=Orlov%2C+Grigory+A.&rft.au=Zyk%2C+Nikolay+Y.&rft.date=2025-04-16&rft.pub=American+Chemical+Society&rft.issn=1043-1802&rft.eissn=1520-4812&rft.volume=36&rft.issue=4&rft.spage=748&rft.epage=761&rft_id=info:doi/10.1021%2Facs.bioconjchem.5c00033&rft.externalDocID=e96468030
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1043-1802&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1043-1802&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1043-1802&client=summon